Mechanisms of translocation of ER chaperones to the cell surface and immunomodulatory roles in cancer and autoimmunity

Frontiers in Oncology

Volumn 5, Issue , 2015, Pages 1-14

  Wiersma, Valerie R ^a   Michalak, Marek ^b,c   Abdullah, Trefa M ^b   Bremer, Edwin ^a,b   Eggleton, Paul ^b,c  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Calreticulin; Damage associated molecular patterns; ER stress; Immunogenic cell death; Modification; Posttranslational

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; AMINO ACID TRANSFER RNA LIGASE; BIOLOGICAL MARKER; CALRETICULIN; CD47 ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR 1C; DNA BINDING PROTEIN; GAMMA INTERFERON; GLUCOSE REGULATED PROTEIN 78; GLUCOSE REGULATED PROTEIN 94; GLYCOPROTEIN GP 96; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HIGH MOBILITY GROUP B1 PROTEIN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE 2; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NITRIC OXIDE; PATHOGEN ASSOCIATED MOLECULAR PATTERN; PHOSPHATIDYLSERINE; PROTEIN DISULFIDE ISOMERASE; PROTEIN TRANSLOCASE; SERINE PROTEINASE INHIBITOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4;

ADAPTIVE IMMUNITY; ARTICLE; AUTOIMMUNITY; CANCER PATIENT; CANCER THERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DEATH; ENDOPLASMIC RETICULUM STRESS; GENE EXPRESSION REGULATION; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; INNATE IMMUNITY; MULTIPLE SCLEROSIS; NONHUMAN; PHAGOCYTE; PROTEIN ASSEMBLY; PROTEIN BINDING; PROTEIN FOLDING; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION;

EID: 84979986084     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2015.00007     Document Type: Article

References (139)

1. Porter KR, Claude A, Fullam EF. A study of tissue culture cells by electron microscopy: methods and preliminary observations. J Exp Med (1945) 81:233-46. doi:10.1084/jem.81.3.233
2. Palade GE, Porter KR. Studies on the endoplasmic reticulum. I. Its identification in cells in situ. J Exp Med (1954) 100:641-56. doi:10.1084/jem.100.6.641
3. Palade G. Intracellular aspects of the process of protein synthesis.Science (1975) 189:347-58. doi:10.1126/science.1096303
4. Palade GE, Siekevitz P. Liver microsomes; an integrated morphological and biochemical study. J Biophys Biochem Cytol (1956) 2:171-200. doi:10.1083/jcb. 2.6.671
5. Mazzarello P, Calligaro A, Vannini V, Muscatello U. The sarcoplasmic reticulum: its discovery and rediscovery. Nat Rev Mol Cell Biol (2003) 4:69-74. doi:10.1038/nrm1003
6. Krieg UC, Johnson AE, Walter P. Protein translocation across the endoplasmic reticulum membrane: identification by photocross-linking of a 39-kD integral membrane glycoprotein as part of a putative translocation tunnel. J Cell Biol (1989) 109:2033-43. doi:10.1083/jcb.109.5.2033
7. Deshaies RJ,SchekmanR.Ayeastmutant defectiveatanearly stageinimportof secretory protein precursors into the endoplasmic reticulum. J Cell Biol (1987) 105:633-45. doi:10.1083/jcb.105.2.633
8. Caro LG, Palade GE. Protein synthesis, storage, and discharge in the pancreatic exocrine cell. An autoradiographic study. J Cell Biol (1964) 20:473-95. doi:10.1083/jcb.20.3.473
9. Schwanhausser B, Busse D, Li N, Dittmar G, Schuchhardt J, Wolf J, et al. Global quantification of mammalian gene expression control. Nature (2011) 473:337-42. doi:10.1038/nature10098
10. Freedman RB. Protein disulfide isomerase: multiple roles in the modification of nascent secretory proteins. Cell (1989) 57:1069-72. doi:10.1016/0092- 8674(89)90043-3
11. Schachter H. The subcellular sites of glycosylation. Biochemical Society Symposium. London: Publisher Portland Press (1974). p. 57-71.
12. Gidalevitz T, Stevens F, Argon Y. Orchestration of secretory protein folding by ER chaperones. Biochim Biophys Acta (2013) 1833:2410-24. doi:10.1016/j. bbamcr.2013.03.007
13. Montero M,Brini M, Marsault R,Alvarez J,Sitia R,Pozzan T, et al. Monitoring dynamic changes in free Ca2+ concentration in the endoplasmic reticulum of intact cells. EMBO J (1995) 14:5467-75.
14. Hirai K, Kikuchi S, Kurita A, Ohashi S, Adachi E, Matsuoka Y, et al. Immunohistochemical distribution of heat shock protein 47 (HSP47) in scirrhous carcinoma of the stomach. Anticancer Res (2006) 26:71-8.
15. Yokota S, Kubota H, Matsuoka Y, Naitoh M, Hirata D, Minota S, et al. Prevalence of HSP47 antigen and autoantibodies to HSP47 in the sera of patients with mixed connective tissue disease. Biochem Biophys Res Commun (2003) 303:413-8. doi:10.1016/S0006-291X(03)00352-8
16. Yamamoto N, Kinoshita T, Nohata N, Yoshino H, Itesako T, Fujimura L, et al. Tumor-suppressive microRNA-29a inhibits cancer cell migration and invasion via targeting HSP47 in cervical squamous cell carcinoma. Int J Oncol (2013) 43:1855-63. doi:10.3892/ijo.2013.2145
17. ZhangY, Liu R, Ni M, Gill P, Lee AS. Cell surface relocalization of the endoplasmic reticulum chaperone and unfolded protein response regulator GRP78/BiP. J Biol Chem (2010) 285:15065-75. doi:10.1074/jbc.M109.087445
18. Li J, Lee AS. Stress induction of GRP78/BiP and its role in cancer. Curr Mol Med (2006) 6:45-54. doi:10.2174/156652406775574523
19. Panayi GS, Corrigall VM. BiP regulates autoimmune inflammation and tissue damage.Autoimmun Rev (2006) 5:140-2. doi:10.1016/j.autrev.2005. 08.006
20. Kosakowska-CholodyT,LinJ,Srideshikan SM,SchefferL,TarasovaNI,Acharya JK. HKH40A downregulates GRP78/BiP expression in cancer cells. Cell Death Dis (2014) 5:e1240. doi:10.1038/cddis.2014.203
21. Panaretakis T, Joza N, Modjtahedi N, Tesniere A, Vitale I, Durchschlag M, et al. The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death. Cell Death Differ (2008) 15:1499-509. doi:10.1038/cdd. 2008.67
22. Dihazi H, Dihazi GH, Bibi A, Eltoweissy M, Mueller CA, Asif AR, et al. Secretion of ERP57 is important for extracellular matrix accumulation and progression of renal fibrosis, and is an early sign of disease onset. J Cell Sci (2013) 126:3649-63. doi:10.1242/jcs.125088
23. Gaucci E, Altieri F, Turano C, Chichiarelli S. The protein ERp57 contributes to EGF receptor signaling and internalization in MDA-MB-468 breast cancer cells. J Cell Biochem (2013) 114:2461-70. doi:10.1002/jcb.24590
24. Leys CM, Nomura S, LaFleur BJ, Ferrone S, Kaminishi M, Montgomery E, et al. Expression and prognostic significance of prothymosin-alpha and ERp57 in human gastric cancer. Surgery (2007) 141:41-50. doi:10.1016/j.surg.2006. 05.009
25. Xu S, Sankar S, Neamati N. Protein disulfide isomerase: a promising target for cancer therapy. Drug Discov Today (2014) 19:222-40. doi:10.1016/j.drudis. 2013.10.017
26. Xu S, Butkevich AN, Yamada R, Zhou Y, Debnath B, Duncan R, et al. Discovery of an orally active small-molecule irreversible inhibitor of protein disulfide isomerase for ovarian cancer treatment. Proc Natl Acad Sci U S A (2012) 109:16348-53. doi:10.1073/pnas.1205226109
27. Dejeans N, Glorieux C,Guenin S, Beck R, Sid B,Rousseau R, et al. Overexpression of GRP94 in breast cancer cells resistant to oxidative stress promotes high levels of cancer cell proliferation and migration: implications for tumor recurrence. Free Radic Biol Med (2012) 52:993-1002. doi:10.1016/j.freeradbiomed. 2011.12.019
28. Zhang L, Wang S, Wangtao Y, Wang J, Wang L, Jiang S, et al. Upregulation of GRP78 and GRP94 and its function in chemotherapy resistance to VP-16 in human lung cancer cell line SK-MES-1. Cancer Invest (2009) 27:453-8. doi:10.1080/07357900802527239
29. Pan Z, Erkan M, Streit S, Friess H, Kleeff J. Silencing of GRP94 expression promotes apoptosis in pancreatic cancer cells. Int J Oncol (2009) 35:823-8. doi:10.3892/ijo_00000395
30. Zhang LY, Zhang XC, Wang LD, Zhang ZF, Li PL. Increased expression of GRP94 protein is associated with decreased sensitivity to adriamycin in ovarian carcinoma cell lines. Clin Exp Obstet Gynecol (2008) 35:257-63.
31. Garg AD, Krysko DV, Vandenabeele P, Agostinis P. Hypericin-based photodynamic therapy induces surface exposure of damage-associated molecular patterns like HSP70 and calreticulin. Cancer Immunol Immunother (2012) 61:215-21. doi:10.1007/s00262-011-1184-2
32. Korbelik M, Zhang W, Merchant S. Involvement of damage-associated molecular patterns in tumor response to photodynamic therapy: surface expression of calreticulin and high-mobility group box-1 release. Cancer Immunol Immunother (2011) 60:1431-7. doi:10.1007/s00262-011-1047-x
33. Zamanian M,Veerakumarasivam A,Abdullah S,Rosli R. Calreticulin and cancer. Pathol Oncol Res (2013) 19:149-54. doi:10.1007/s12253-012-9600-2
34. Gold LI, Eggleton P, Sweetwyne MT, Van Duyn LB, Greives MR, Naylor SM, et al. Calreticulin: non-endoplasmic reticulum functions in physiology and disease. FASEB J (2010) 24:665-83. doi:10.1096/fj.09-145482
35. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature (2002) 418:191-5. doi:10.1038/ nature00858
36. Dumitriu IE, Baruah P, Valentinis B,Voll RE, Herrmann M, Nawroth PP, et al. Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J Immunol (2005) 174:7506-15. doi:10.4049/jimmunol.174.12.7506
37. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science (1999) 285:248-51. doi:10.1126/science.285.5425.248
38. Tamura Y, Hirohashi Y, Kutomi G, Nakanishi K, Kamiguchi K, Torigoe T, et al. Tumor-produced secreted form of binding of immunoglobulin protein elicits antigen-specific tumor immunity. J Immunol (2011) 186:4325-30. doi:10.4049/jimmunol.1004048
39. Udono H, Levey DL, Srivastava PK. Cellular requirements for tumor-specific immunity elicited by heat shock proteins: tumor rejection antigen gp96 primes CD8+ T cells in vivo. Proc Natl Acad Sci U S A (1994) 91:3077-81. doi:10.1073/pnas.91.8.3077
40. Bodman-Smith MD, Fife MF, Wythe H, Corrigal VM, Panayi GS, Wedderburn LR, et al. Anti-BiP antibody levels in juvenile idiopathic arthritis (JIA). Rheumatology (2004) 43:1305-6. doi:10.1093/rheumatology/keh186
41. Eggleton P, Reid KB, Kishore U, Sontheimer RD. Clinical relevance of calreticulin in systemic lupus erythematosus. Lupus (1997) 6:564-71. doi:10.1177/ 096120339700600703
42. Kishore U,Sontheimer RD, Sastry KN, Zappi EG, Hughes GR, Khamashta MA, et al. The systemic lupus erythematosus (SLE) disease autoantigen-calreticulin can inhibit C1q associationwith immune complexes.Clin Exp Immunol (1997) 108:181-90. doi:10.1046/j.1365-2249.1997.3761273.x
43. TarrJM,Winyard PG,Ryan B,Harries LW, Haigh R,Viner N,et al. Extracellular calreticulin is present in the joints of patients with rheumatoid arthritis and inhibits FasL (CD95L)-mediated apoptosis of T cells. Arthritis Rheum (2010) 62:2919-29. doi:10.1002/art.27602
44. Weber CK, Haslbeck M, Englbrecht M, Sehnert B, Mielenz D, Graef D, et al. Antibodies to the endoplasmic reticulum-resident chaperones calnexin, BiP and Grp94 in patients with rheumatoid arthritis and systemic lupus erythematosus. Rheumatology (2010) 49:2255-63. doi:10.1093/rheumatology/ keq272
45. Ling S, Cline EN, Haug TS, Fox DA, Holoshitz J. Citrullinated calreticulin potentiates rheumatoid arthritis shared epitope signaling. Arthritis Rheum (2013) 65:618-26. doi:10.1002/art.37814
46. LingS,LaiA,BorschukovaO,Pumpens P,Holoshitz J.Activationof nitric oxide signaling by the rheumatoid arthritis shared epitope. Arthritis Rheum (2006) 54:3423-32. doi:10.1002/art.22178
47. Basu S, Binder RJ, Ramalingam T, Srivastava PK. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity (2001) 14:303-13. doi:10.1016/S1074-7613(01)00111-X
48. Srivastava P. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu Rev Immunol (2002) 20:395-425. doi:10.1146/annurev.immunol.20.100301. 064801
49. Berwin B, Reed RC, Nicchitta CV. Virally induced lytic cell death elicits the release of immunogenic GRP94/gp96. J Biol Chem (2001) 276:21083-8. doi:10.1074/jbc.M101836200
50. Garg AD, Krysko DV, Verfaillie T, Kaczmarek A, Ferreira GB, Marysael T, et al. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J (2012) 31:1062-79. doi:10.1038/ emboj.2011.497
51. Clark PR, Menoret A. The inducible Hsp70 as a marker of tumor immunogenicity. Cell Stress Chaperones (2001) 6:121-5. doi:10.1379/1466-1268(2001) 006<0121:TIHAAM>2.0.CO;2
52. Feng H, Zeng Y, Whitesell L, Katsanis E. Stressed apoptotic tumor cells express heat shock proteins and elicit tumor-specific immunity. Blood (2001) 97:3505-12. doi:10.1182/blood.V97.11.3505
53. Feng H, Zeng Y, Graner MW, Katsanis E. Stressed apoptotic tumor cells stimulate dendritic cells and induce specific cytotoxic T cells. Blood (2002) 100:4108-15. doi:10.1182/blood-2002-05-1389
54. Feng H, Zeng Y, Graner MW, Likhacheva A, Katsanis E. Exogenous stress proteins enhance the immunogenicity of apoptotic tumor cells and stimulate antitumor immunity. Blood (2003) 101:245-52. doi:10.1182/blood-2002-05- 1580
55. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med (2007) 13:54-61. doi:10.1038/nm1523
56. Vandivier RW, Ogden CA, Fadok VA, Hoffmann PR, Brown KK, Botto M, et al. Role of surfactant proteins A, D, and C1q in the clearance of apoptotic cells in vivo and in vitro: calreticulin and CD91 as a common collectin receptor complex. J Immunol (2002) 169:3978-86. doi:10.4049/jimmunol.169.7.3978
57. Donnelly S,Roake W,Brown S,Young P,Naik H,Wordsworth P,et al. Impaired recognition of apoptotic neutrophils by the C1q/calreticulin and CD91 pathway in systemic lupus erythematosus. Arthritis Rheum (2006) 54:1543-56. doi:10.1002/art.21783
58. Chao MP, JaiswalS,Weissman-Tsukamoto R,AlizadehAA,Gentles AJ,Volkmer J, et al. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med (2010) 2:63ra94. doi:10.1126/scitranslmed.3001375
59. Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, et al. Anti- CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell (2010) 142:699-713. doi:10.1016/j.cell. 2010.07.044
60. Gardai SJ, McPhillips KA,Frasch SC, Janssen WJ, Starefeldt A, Murphy-Ullrich JE, et al. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell (2005) 123:321-34. doi:10.1016/j.cell.2005.08.032
61. Kepp O, Gdoura A, Martins I, Panaretakis T, Schlemmer F, Tesniere A, et al. Lysyl tRNA synthetase is required for the translocation of calreticulin to the cell surface in immunogenic death. Cell Cycle (2010) 9:3072-7. doi:10.4161/cc.9.15.12459
62. Obeid M. ERP57 membrane translocation dictates the immunogenicity of tumor cell death by controlling the membrane translocation of calreticulin. J Immunol (2008) 181:2533-43. doi:10.4049/jimmunol.181.4.2533
63. Ni M, Wei W, Wang Y, Zhang N, Ding H, Shen C, et al. Serum levels of calreticulin in correlation with disease activity in patients with rheumatoid arthritis. J Clin Immunol (2013) 33:947-53. doi:10.1007/s10875-013-9885-2
64. Kinoshita G,Purcell AW, Keech CL, Farris AD, McCluskey J,Gordon TP. Molecular chaperones are targets of autoimmunity in Ro(SS-A) immune mice. Clin Exp Immunol (1999) 115:268-74. doi:10.1046/j.1365-2249.1999.00794.x
65. Casciola-Rosen LA,AnhaltG,RosenA.Autoantigens targetedinsystemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med (1994) 179:1317-30. doi:10.1084/jem.179.4. 1317
66. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol (1994) 12:991-1045. doi:10.1146/annurev.immunol.12.1.991
67. Komurasaki R, Imaoka S, Tada N,Okada K,Nishiguchi S,FunaeY. LKM-1 sera from autoimmune hepatitis patients that recognize ERp57, carboxylesterase 1 and CYP2D6.Drug Metab Pharmacokinet (2010) 25:84-92. doi:10.2133/dmpk. 25.84
68. Watanabe K, Ohira H, Orikasa H, Saito K, Kanno K, Shioya Y, et al. Anticalreticulin antibodies in patients with inflammatory bowel disease. Fukushima J Med Sci (2006) 52:1-11. doi:10.5387/fms.52.1
69. SuzukiS,UtsugisawaK,IwasaK,SatohT,NaganeY,YoshikawaH,et al.Autoimmunity to endoplasmic reticulum chaperone GRP94 in myasthenia gravis. J Neuroimmunol (2011) 237:87-92. doi:10.1016/j.jneuroim.2011.06.011
70. Kreisel W, Siegel A,Bahler A, Spamer C,Schiltz E, Kist M,et al. High prevalence of antibodies to calreticulin of the IgA class in primary biliary cirrhosis: a possible role of gut-derived bacterial antigens in its aetiology? Scand J Gastroenterol (1999) 34:623-8. doi:10.1080/003655299750026100
71. GoebV,Thomas-L'Otellier M,Daveau R,Charlionet R,Fardellone P,LeLoet X, et al. Candidate autoantigens identifiedbymassspectrometry in early rheumatoid arthritis are chaperones and citrullinated glycolytic enzymes. Arthritis Res Ther (2009) 11:R38. doi:10.1186/ar2644
72. Eggleton P, Ward FJ, Johnson S, Khamashta MA, Hughes GR, Hajela VA, et al. Fine specificity of autoantibodies to calreticulin: epitope mapping and characterization. Clin Exp Immunol (2000) 120:384-91. doi:10.1046/j.1365-2249. 2000.01214.x
73. Nagayama S,Yokoi T,Tanaka H, KawaguchiY, Shirasaka T,Kamataki T. Occurrence of autoantibody to protein disulfide isomerase in patients with hepatic disorder. J Toxicol Sci (1994) 19:163-9. doi:10.2131/jts.19.3_155
74. Raiter A, Vilkin A, Gingold R, Levi Z, Halpern M, Niv Y, et al. The presence of anti-GRP78 antibodies in the serum of patients with colorectal carcinoma: a potential biomarker for early cancer detection. Int J Biol Markers (2014) 29:e431-5. doi:10.5301/jbm.5000086
75. Sanchez D, Palova-Jelinkova L, Felsberg J,Simsova M,Pekarikova A, Pecharova B, et al. Anti-calreticulin immunoglobulin A (IgA) antibodies in refractory coeliac disease. Clin Exp Immunol (2008) 153:351-9. doi:10.1111/j.1365-2249. 2008.03701.x
76. Hong SH, Misek DE, Wang H, Puravs E, Giordano TJ, Greenson JK, et al. An autoantibody-mediated immune response to calreticulin isoforms in pancreatic cancer. Cancer Res (2004) 64:5504-10. doi:10.1158/0008-5472.CAN-04- 0077
77. Liu Y, He J, Xie X, Su G, Teitz-Tennenbaum S, Sabel MS, et al. Serum autoantibody profiling using a natural glycoprotein microarray for the prognosis of early melanoma. J Proteome Res (2010) 9:6044-51. doi:10.1021/pr100856k
78. PlatetN,Cunat S,Chalbos D,RochefortH,GarciaM. Unliganded and liganded estrogen receptors protect against cancer invasion via different mechanisms. Mol Endocrinol (2000) 14:999-1009. doi:10.1210/mend.14.7.0492
79. Arnaudeau S, Frieden M, Nakamura K, Castelbou C, Michalak M, Demaurex N. Calreticulin differentially modulates calcium uptake and release in the endoplasmic reticulum and mitochondria. J Biol Chem (2002) 277:46696-705. doi:10.1074/jbc.M202395200
80. Chen CN, Chang CC,Su TE, Hsu WM,JengYM,HoMC,et al. Identification of calreticulin as a prognosis marker and angiogenic regulator in human gastric cancer. Ann Surg Oncol (2009) 16:524-33. doi:10.1245/s10434-008-0243-1
81. Lu YC, Chen CN, Wang B, Hsu WM, Chen ST, Chang KJ, et al. Changes in tumor growth and metastatic capacities of J82 human bladder cancer cells suppressed by down-regulation of calreticulin expression. Am J Pathol (2011) 179:1425-33. doi:10.1016/j.ajpath.2011.05.015
82. Kageyama S, Isono T, Iwaki H,Wakabayashi Y, Okada Y,Kontani K, et al. Identification by proteomic analysis of calreticulin as a marker for bladder cancer and evaluation of the diagnostic accuracy of its detection in urine. Clin Chem (2004) 50:857-66. doi:10.1373/clinchem.2003.027425
83. Liu R, Gong J, Chen J, Li Q, Song C, Zhang J, et al. Calreticulin as a potential diagnostic biomarker for lung cancer. Cancer Immunol Immunother (2012) 61:855-64. doi:10.1007/s00262-011-1146-8
84. Song MN, Moon PG, Lee JE, Na M, Kang W, Chae YS, et al. Proteomic analysis of breast cancer tissues to identify biomarker candidates by gel-assisted digestion and label-free quantification methods using LC-MS/MS. Arch Pharm Res (2012) 35:1839-47. doi:10.1007/s12272-012-1018-6
85. Galazis N, Olaleye O, Haoula Z, Layfield R, Atiomo W. Proteomic biomarkers for ovarian cancer risk in women with polycystic ovary syndrome: a systematic review and biomarker database integration. Fertil Steril (2012) 98:1590.e-601.e. doi:10.1016/j.fertnstert.2012.08.002
86. Morelli M, Scumaci D, Di Cello A, Venturella R, Donato G, Faniello MC, et al. DJ-1 in endometrial cancer: a possible biomarker to improve differential diagnosis between subtypes. Int J Gynecol Cancer (2014) 24:649-58. doi:10.1097/IGC.0000000000000102
87. Yoon GS, Lee H, Jung Y, Yu E, Moon HB, Song K, et al. Nuclear matrix of calreticulin in hepatocellular carcinoma. Cancer Res (2000) 60:1117-20.
88. Alaiya A, Roblick U, Egevad L, Carlsson A, Franzen B, Volz D, et al. Polypeptide expression in prostate hyperplasia and prostate adenocarcinoma. Anal Cell Pathol (2000) 21:1-9. doi:10.1155/2000/351963
89. Alur M, Nguyen MM, Eggener SE, Jiang F, Dadras SS, Stern J, et al. Suppressive roles of calreticulin in prostate cancer growth and metastasis. Am J Pathol (2009) 175:882-90. doi:10.2353/ajpath.2009.080417
90. Liu X, Ji J, Forsti A, Sundquist K, Sundquist J, Hemminki K. Autoimmune disease and subsequent urological cancer. J Urol (2013) 189:2262-8. doi:10.1016/j.juro.2012.12.014
91. Hemminki K, Liu X, Forsti A, Ji J, Sundquist J, Sundquist K. Subsequent leukaemia in autoimmune disease patients. Br J Haematol (2013) 161:677-87. doi:10.1111/bjh.12330
92. Hemminki K, Liu X, Forsti A, Ji J, Sundquist J, Sundquist K. Subsequent brain tumors in patients with autoimmune disease. Neuro Oncol (2013) 15:1142-50. doi:10.1093/neuonc/not070
93. Castro FA, Liu X, Forsti A, Ji J, Sundquist J, Sundquist K, et al. Increased risk of hepatobiliary cancers after hospitalization for autoimmune disease. Clin Gastroenterol Hepatol (2014) 12:1038-45.e7. doi:10.1016/j.cgh.2013.11.007
94. Aguilar-Guzman L, Lobos-Gonzalez L, Rosas C, Vallejos G, Falcon C, Sosoniuk E, et al. Human survivin and Trypanosoma cruzi calreticulin act in synergy against a murine melanoma in vivo. PLoS One (2014) 9:e95457. doi:10.1371/journal.pone.0095457
95. RamirezG,ValckC,AguilarL,KemmerlingU,Lopez-MunozR,CabreraG,et al. Roles of Trypanosoma cruzi calreticulin in parasite-host interactions and in tumor growth. Mol Immunol (2012) 52:133-40. doi:10.1016/j.molimm.2012. 05.006
96. Lopez NC, Valck C, Ramirez G, Rodriguez M, Ribeiro C, Orellana J, et al. Antiangiogenic and antitumor effects of Trypanosoma cruzi calreticulin. PLoS Negl Trop Dis (2010) 4:e730. doi:10.1371/journal.pntd.0000730
97. Munro S, Pelham HR. A C-terminal signal prevents secretion of luminal ER proteins. Cell (1987) 48:899-907. doi:10.1016/0092-8674(87)90086-9
98. Altmeyer A, Maki RG, Feldweg AM, Heike M, Protopopov VP, Masur SK, et al. Tumor-specific cell surface expression of the-KDEL containing, endoplasmic reticular heat shock protein gp96. Int J Cancer (1996) 69:340-9. doi:10.1002/(SICI)1097-0215(19960822)69:4<340::AID-IJC18>3.0.CO;2-9
99. RobertJ,MenoretA,CohenN.Cell surfaceexpressionof the endoplasmic reticular heat shock protein gp96 is phylogenetically conserved. J Immunol (1999) 163:4133-9.
100. Wiest DL, Bhandoola A, Punt J, Kreibich G, McKean D, Singer A. Incomplete endoplasmic reticulum (ER) retention in immature thymocytes as revealed by surface expression of "ER-resident" molecular chaperones. Proc Natl Acad Sci U S A (1997) 94:1884-9. doi:10.1073/pnas.94.5.1884
101. Sauk JJ, Norris K, Hebert C, Ordonez J, Reynolds M. Hsp47 binds to the KDEL receptor and cell surface expression is modulated by cytoplasmic and endosomal pH. Connect Tissue Res (1998) 37:105-19. doi:10.3109/ 03008209809028904
102. NangaliaJ,Massie CE, Baxter EJ,Nice FL,Gundem G,Wedge DC,et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med (2013) 369:2391-405. doi:10.1056/NEJMoa1312542
103. Vannucchi AM, Rotunno G, Bartalucci N, Raugei G, Carrai V, Balliu M, et al. Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value. Leukemia (2014) 28:1811-8. doi:10.1038/leu.2014.100
104. Capitani M, Sallese M. The KDEL receptor: new functions for an old protein. FEBS Lett (2009) 583:3863-71. doi:10.1016/j.febslet.2009.10.053
105. Cancino J, Jung JE, Luini A. Regulation of Golgi signaling and trafficking by the KDEL receptor. Histochem Cell Biol (2013) 140:395-405. doi:10.1007/s00418- 013-1130-9
106. Han JM, Park SG, Liu B, Park BJ, Kim JY, Jin CH, et al. Aminoacyl-tRNA synthetase-interacting multifunctional protein 1/p43 controls endoplasmic reticulum retention of heat shock protein gp96: its pathological implications in lupus-like autoimmune diseases. Am J Pathol (2007) 170:2042-54. doi:10.2353/ajpath.2007.061266
107. Townsley FM, Wilson DW, Pelham HR. Mutational analysis of the human KDEL receptor: distinct structural requirements for Golgi retention, ligand binding and retrograde transport. EMBO J (1993) 12:2821-9.
108. PulvirentiT,GiannottaM,CapestranoM,CapitaniM,PisanuA,PolishchukRS, et al. A traffic-activated Golgi-based signalling circuit coordinates the secretory pathway. Nat Cell Biol (2008) 10:912-22. doi:10.1038/ncb1751
109. Giannotta M, Ruggiero C, Grossi M, Cancino J, Capitani M, Pulvirenti T, et al. The KDEL receptor couples to Galphaq/11 to activate Src kinases and regulate transport through the Golgi. EMBO J (2012) 31:2869-81. doi:10.1038/emboj. 2012.134
110. Panaretakis T,Kepp O,Brockmeier U,TesniereA,Bjorklund AC,Chapman DC, et al. Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J (2009) 28:578-90. doi:10.1038/emboj.2009.1
111. Denning GM, Leidal KG, Holst VA, Iyer SS, Pearson DW, Clark JR, et al. Calreticulin biosynthesis and processing in human myeloid cells: demonstration of signal peptide cleavage and N-glycosylation. Blood (1997) 90:372-81.
112. Tarr JM, Young PJ, Morse R, Shaw DJ, Haigh R, Petrov PG, et al. A mechanism of release of calreticulin from cells during apoptosis. J Mol Biol (2010) 401:799-812. doi:10.1016/j.jmb.2010.06.064
113. Tsai B, Ye Y, Rapoport TA. Retro-translocation of proteins from the endoplasmic reticulum into the cytosol. Nat Rev Mol Cell Biol (2002) 3:246-55. doi:10.1038/nrm780
114. Afshar N, Black BE, Paschal BM. Retrotranslocation of the chaperone calreticulin from the endoplasmic reticulum lumentothe cytosol.Mol Cell Biol (2005) 25:8844-53. doi:10.1128/MCB.25.20.8844-8853.2005
115. Holaska JM, Black BE, Love DC, Hanover JA, Leszyk J, Paschal BM. Calreticulin is a receptor for nuclear export. J Cell Biol (2001) 152:127-40. doi:10.1083/jcb.152.1.127
116. Lopez Sambrooks C,Carpio MA,Hallak ME. Arginylated calreticulinatplasma membrane increases susceptibility of cells to apoptosis. J Biol Chem (2012) 287:22043-54. doi:10.1074/jbc.M111.338335
117. Saha S, Kashina A. Posttranslational arginylation as a global biological regulator. Dev Biol (2011) 358:1-8. doi:10.1016/j.ydbio.2011.06.043
118. Wang J, Han X,Wong CC, Cheng H, Aslanian A, Xu T, et al. Arginyltransferase ATE1 catalyzes midchain arginylation of proteins at side chain carboxylates in vivo. Chem Biol (2014) 21:331-7. doi:10.1016/j.chembiol.2013.12.017
119. Decca MB, Carpio MA, Bosc C, Galiano MR, Job D, Andrieux A, et al. Posttranslational arginylation of calreticulin: a new isospecies of calreticulin component of stress granules. J Biol Chem (2007) 282:8237-45. doi:10.1074/jbc. M608559200
120. Ling S, Cheng A, Pumpens P, Michalak M, Holoshitz J. Identification of the rheumatoid arthritis shared epitope binding site on calreticulin. PLoS One (2010) 5:e11703. doi:10.1371/journal.pone.0011703
121. LingS,Pi X,HoloshitzJ.The rheumatoidarthritisshared epitope triggers innate immune signaling via cell surface calreticulin. J Immunol (2007) 179:6359-67. doi:10.4049/jimmunol.179.9.6359
122. Multhoff G, Hightower LE. Cell surface expression of heat shock proteins and the immune response. Cell Stress Chaperones (1996) 1:167-76. doi:10.1379/ 1466-1268(1996)001<0167:CSEOHS>2.3.CO;2
123. Arispe N, De Maio A. ATP and ADP modulate a cation channel formed by Hsc70 in acidic phospholipid membranes. J Biol Chem (2000) 275:30839-43. doi:10.1074/jbc.M005226200
124. Paidassi H, Tacnet-Delorme P, Verneret M, Gaboriaud C, Houen G, Duus K, et al. Investigations on the C1q-calreticulin-phosphatidylserine interactions yield new insights into apoptotic cell recognition. J Mol Biol (2011) 408:277-90. doi:10.1016/j.jmb.2011.02.029
125. Oyadomari S, Takeda K, Takiguchi M, Gotoh T, Matsumoto M, Wada I, et al. Nitric oxide-induced apoptosis in pancreatic beta cells is mediated by the endoplasmic reticulum stress pathway.Proc Natl Acad SciUSA (2001) 98:10845-50. doi:10.1073/pnas.191207498
126. Patel JM,LiYD,ZhangJ,GelbandCH,Raizada MK,Block ER. Increased expression of calreticulin is linked to ANG IV-mediated activation of lung endothelial NOS. Am J Physiol (1999) 277:L794-801.
127. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Tolllike receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med (2007) 13:1050-9. doi:10.1038/ nm1622
128. Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1betadependent adaptive immunity against tumors. Nat Med (2009) 15:1170-8. doi:10.1038/nm.2028
129. D'Eliseo D, Manzi L, Velotti F. Capsaicin as an inducer of damage-associated molecular patterns (DAMPs)of immunogenic cell death (ICD)inhuman bladder cancer cells. Cell Stress Chaperones (2013) 18:801-8. doi:10.1007/s12192- 013-0422-2
130. Peters LR, Raghavan M. Endoplasmic reticulum calcium depletion impacts chaperone secretion, innate immunity, and phagocytic uptake of cells. J Immunol (2011) 187:919-31. doi:10.4049/jimmunol.1100690
131. Wemeau M, Kepp O, Tesniere A, Panaretakis T, Flament C, De Botton S, et al. Calreticulin exposure on malignant blasts predicts a cellular anticancer immune response in patients with acute myeloid leukemia. Cell Death Dis (2010) 1:e104. doi:10.1038/cddis.2010.82
132. Kepp O, Galluzzi L, Giordanetto F, Tesniere A, Vitale I, Martins I, et al. Disruption of the PP1/GADD34 complex induces calreticulin exposure. Cell Cycle (2009) 8:3971-7. doi:10.4161/cc.8.23.10191
133. Martins I, Kepp O, Schlemmer F,Adjemian S, Tailler M, Shen S, et al. Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress. Oncogene (2011) 30:1147-58. doi:10.1038/onc.2010.500
134. TufiR, PanaretakisT,Bianchi K,CriolloA,Fazi B,Di Sano F,et al. Reduction of endoplasmic reticulum Ca2+ levels favors plasma membrane surface exposure of calreticulin. Cell Death Differ (2008) 15:274-82. doi:10.1038/sj.cdd.4402275
135. Zappasodi R, Pupa SM, Ghedini GC, Bongarzone I, Magni M, Cabras AD, et al. Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death. Cancer Res (2010) 70:9062-72. doi:10.1158/0008-5472.CAN-10-1825
136. FucikovaJ,KralikovaP,FialovaA,BrtnickyT,RobL,BartunkovaJ,et al. Human tumor cells killedby anthracyclines inducea tumor-specific immune response. Cancer Res (2011) 71:4821-33. doi:10.1158/0008-5472.CAN-11-0950
137. Menger L, Vacchelli E, Adjemian S, Martins I, Ma Y, Shen S, et al. Cardiac glycosides exert anticancer effects by inducing immunogenic cell death. Sci Transl Med (2012) 4:143ra99. doi:10.1126/scitranslmed.3003807
138. Fredly H, Ersvaer E, Gjertsen BT, Bruserud O. Immunogenic apoptosis in human acute myeloid leukemia (AML): primary human AML cells expose calreticulin and release heat shock protein (HSP) 70and HSP90 during apoptosis. Oncol Re p (2011) 25:1549-56. doi:10.3892/or.2011.1229
139. Jeffery E, Peters LR, Raghavan M. The polypeptide binding conformation of calreticulin facilitates its cell-surface expression under conditions of endoplasmic reticulum stress. J Biol Chem (2011) 286:2402-15. doi:10.1074/jbc.M110. 180877